Literature DB >> 12954760

The structural integrity exerted by N-terminal pyroglutamate is crucial for the cytotoxicity of frog ribonuclease from Rana pipiens.

You-Di Liao1, Sui-Chi Wang, Ying-Jen Leu, Chiu-Feng Wang, Shu-Ting Chang, Yu-Ting Hong, Yun-Ru Pan, Chinpan Chen.   

Abstract

Onconase, a cytotoxic ribonuclease from Rana pipiens, possesses pyroglutamate (Pyr) at the N-terminus and has a substrate preference for uridine-guanine (UG). To identify residues responsible for onconase's cytotoxicity, we cloned the rpr gene from genomic DNA and expressed it in Escherichia coli BL21(DE3). The recombinant onconase with Met at the N-terminus had reduced thermostability, catalytic activity and antigenicity. Therefore, we developed two methods to produce onconase without Met. One relied on the endogeneous E.coli methionine aminopeptidase and the other relied on the cleavage of a pelB signal peptide. The Pyr1 substitutional variants maintained similar secondary structures to wild-type onconase, but with less thermostability and specific catalytic activity for the innate substrate UG. However, the non-specific catalytic activity for total RNAs varied depending on the relaxation of base specificity. Pyr1 promoted the structural integrity by forming a hydrogen bond network through Lys9 in alpha1 and Val96 in beta6, and participated in catalytic activity by hydrogen bonds to Lys9 and P(1) catalytic phosphate. Residues Thr35 and Asp67 determined B(1) base specificity, and Glu91 determined B(2) base specificity. The cytotoxicity of onconase is largely determined by structural integrity and specific catalytic activity for UG through Pyr1, rather than non-specific activity for total RNAs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954760      PMCID: PMC203329          DOI: 10.1093/nar/gkg746

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  36 in total

1.  RefSeq and LocusLink: NCBI gene-centered resources.

Authors:  K D Pruitt; D R Maglott
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

2.  Ribonuclease A.

Authors:  Ronald T. Raines
Journal:  Chem Rev       Date:  1998-05-07       Impact factor: 60.622

3.  New and cryptic biological messages from RNases.

Authors:  G D'Alessio
Journal:  Trends Cell Biol       Date:  1993-04       Impact factor: 20.808

4.  Contribution of chain termini to the conformational stability and biological activity of onconase.

Authors:  E Notomista; F Catanzano; G Graziano; S Di Gaetano; G Barone; A Di Donato
Journal:  Biochemistry       Date:  2001-08-07       Impact factor: 3.162

5.  Purification and cloning of cytotoxic ribonucleases from Rana catesbeiana (bullfrog).

Authors:  Y D Liao; H C Huang; Y J Leu; C W Wei; P C Tang; S C Wang
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

6.  Molecular cloning of four novel murine ribonuclease genes: unusual expansion within the ribonuclease A gene family.

Authors:  D Batten; K D Dyer; J B Domachowske; H F Rosenberg
Journal:  Nucleic Acids Res       Date:  1997-11-01       Impact factor: 16.971

7.  A combined kinetic and modeling study of the catalytic center subsites of human angiogenin.

Authors:  N Russo; K R Acharya; B L Vallee; R Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

8.  In vitro studies on selective inhibition of tumor cell growth by seminal ribonuclease.

Authors:  S Vescia; D Tramontano; G Augusti-Tocco; G D'Alessio
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

9.  Comparative base specificity, stability, and lectin activity of two lectins from eggs of Rana catesbeiana and R. japonica and liver ribonuclease from R. catesbeiana.

Authors:  Y Okabe; N Katayama; M Iwama; H Watanabe; K Ohgi; M Irie; K Nitta; H Kawauchi; Y Takayanagi; F Oyama
Journal:  J Biochem       Date:  1991-05       Impact factor: 3.387

10.  Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease.

Authors:  G J Gleich; D A Loegering; M P Bell; J L Checkel; S J Ackerman; D J McKean
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

View more
  10 in total

Review 1.  The Potential of a Protein Model Synthesized Absent of Methionine.

Authors:  Ronald J Savino; Bartosz Kempisty; Paul Mozdziak
Journal:  Molecules       Date:  2022-06-08       Impact factor: 4.927

Review 2.  Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.

Authors:  W Ardelt; K Shogen; Z Darzynkiewicz
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

Review 3.  Ribonucleases as potential modalities in anticancer therapy.

Authors:  Wojciech Ardelt; Barbara Ardelt; Zbigniew Darzynkiewicz
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

4.  Removal of N-terminal methionine from recombinant proteins by engineered E. coli methionine aminopeptidase.

Authors:  You-Di Liao; Jen-Chong Jeng; Chiu-Feng Wang; Sui-Chi Wang; Shu-Ting Chang
Journal:  Protein Sci       Date:  2004-07       Impact factor: 6.725

5.  Use of signal sequences as an in situ removable sequence element to stimulate protein synthesis in cell-free extracts.

Authors:  Jin-Ho Ahn; Mi-Yeon Hwang; Kyung-Ho Lee; Cha-Yong Choi; Dong-Myung Kim
Journal:  Nucleic Acids Res       Date:  2006-12-20       Impact factor: 16.971

Review 6.  Strategies to Enhance Periplasmic Recombinant Protein Production Yields in Escherichia coli.

Authors:  Alexandros Karyolaimos; Jan-Willem de Gier
Journal:  Front Bioeng Biotechnol       Date:  2021-12-14

7.  Diverse protein manipulations with genetically encoded glutamic acid benzyl ester.

Authors:  Xiaochen Yang; Hui Miao; Ruotong Xiao; Luyao Wang; Yan Zhao; Qifan Wu; Yanli Ji; Juanjuan Du; Hongqiang Qin; Weimin Xuan
Journal:  Chem Sci       Date:  2021-06-17       Impact factor: 9.825

8.  Towards tricking a pathogen's protease into fighting infection: the 3D structure of a stable circularly permuted onconase variant cleavedby HIV-1 protease.

Authors:  Mariona Callís; Soraya Serrano; Antoni Benito; Douglas V Laurents; Maria Vilanova; Marta Bruix; Marc Ribó
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

9.  A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.

Authors:  Tobias Weber; Athanasios Mavratzas; Stefan Kiesgen; Stephanie Haase; Benedikt Bötticher; Evelyn Exner; Walter Mier; Ludger Grosse-Hovest; Dirk Jäger; Michaela A E Arndt; Jürgen Krauss
Journal:  J Immunol Res       Date:  2015-10-28       Impact factor: 4.818

10.  Linked production of pyroglutamate-modified proteins via self-cleavage of fusion tags with TEV protease and autonomous N-terminal cyclization with glutaminyl cyclase in vivo.

Authors:  Yan-Ping Shih; Chi-Chi Chou; Yi-Ling Chen; Kai-Fa Huang; Andrew H-J Wang
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.